Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03030794
Other study ID # H160047
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 2016
Est. completion date June 2019

Study information

Verified date August 2018
Source Veterans Medical Research Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to assess the effect of repetitive transcranial magnetic stimulation (rTMS) on Gulf War illness related headaches and pain.


Description:

Headaches (HA) and wide spread pain are some of the most common debilitating symptoms in Gulf War Veterans (GWV) with Gulf War Illness (GWI). Migraine like HA and diffuse body pain were detected in 64% of GWV with GWI. This high prevalence of chronic HA and diffuse body pain conditions are often associated with neuropsychological dysfunction in mood, attention, memory and other systemic symptoms, which cast a profound negative impact on patients' quality of life. Unfortunately, conventional pharmacological treatments for GWI related headaches and pain (GWI-HAP) has not been shown to be effective and drugs such as narcotics contain many long term untoward psychosomatic and abusive side effects. Therefore, developing and validating non-invasive and low risk innovative treatment for this patient population is warranted. Transcranial Magnetic Stimulation (TMS) is currently a US FDA approved treatment for major depression and migraine HA.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date June 2019
Est. primary completion date June 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Criteria for veterans with Gulf War Illness headaches and pain:

Inclusion Criteria:

- Male or female between ages 18-65

- CDC Criteria for GWI

- Kansas Criteria for GWI

- International Headache Society Criteria for Migraine HA w/o aura

- Average Headache Exacerbation Intensity >3 on 0-10 NPRS

- Average Overall Daily Muscle Pain Intensity >3 on 0-10 NPRS

- Average Overall Daily Extremities Joint Pain Intensity >3 on 0-10 NPRS

- Headache Exacerbation/Attack = 3 times/week, lasting >4 hrs in past 3 months

Exclusion Criteria:

- Pregnancy

- History of pacemaker implant

- Any ferromagnetic (e.g. bullet fragment, shrapnel, device implant) in the brain or body that will prohibit the patients from having a brain MRI

- History of dementia, major psychiatric diseases, or life threatening diseases

- Presence of any other chronic neuropathic pain states such as Complex Regional Pain Syndrome or Painful Peripheral Neuropathy

- History of seizure

- Pending litigation

- Low back pain with mechanical origins such as lumbar radiculopathy or radiculitis or lumbar facet arthropathy

- Lack of ability to understand the experimental protocol and to adequately communicate in English

- History of Traumatic Brain injury

- Chronic Tension or Cluster Headache

- Ongoing Cognitive Rehabilitation or Treatment of PTSD

Criteria for healthy veterans without Gulf War Illness headaches and pain:

Inclusion Criteria:

- Male or female between ages 18-65

- Served at least 30 consecutive days in the Persian Gulf between 8/90-7/91

Exclusion Criteria:

- CDC Criteria for GWI

- Kansas Criteria for GWI

- International Headache Society Criteria for Migraine HA w/o aura

- Average Headache Exacerbation Intensity >3 on 0-10 NPRS

- Average Overall Daily Muscle Pain Intensity >3 on 0-10 NPRS

- Average Overall Daily Extremities Joint Pain Intensity >3 on 0-10 NPRS

- Headache Exacerbation/Attack = 3 times/week, lasting >4 hrs in past 3 months

- Pregnancy

- History of pacemaker implant

- Any ferromagnetic (e.g. bullet fragment, shrapnel, device implant) in the brain or body that will prohibit the patients from having a brain MRI

- History of dementia, major psychiatric diseases, or life threatening diseases

- Presence of any other chronic neuropathic pain states such as Complex Regional Pain Syndrome or Painful Peripheral Neuropathy

- History of seizure

- Pending litigation

- Low back pain with mechanical origins such as lumbar radiculopathy or radiculitis or lumbar facet arthropathy

- Lack of ability to understand the experimental protocol and to adequately communicate in English

- History of Traumatic Brain injury

- Chronic Tension or Cluster Headache

- Ongoing Cognitive Rehabilitation or Treatment of PTSD

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Repetitive transcranial magnetic stimulation
A non-invasive method of brain stimulation that emits a magnetic pulse.
Repetitive transcranial magnetic stimulation (sham)
No brain stimulation will be administered.

Locations

Country Name City State
United States Naval Medical Center San Diego San Diego California
United States Veteran Affairs Hospital San Diego California

Sponsors (2)

Lead Sponsor Collaborator
Veterans Medical Research Foundation United States Department of Defense

Country where clinical trial is conducted

United States, 

References & Publications (2)

Leung A, Donohue M, Xu R, Lee R, Lefaucheur JP, Khedr EM, Saitoh Y, André-Obadia N, Rollnik J, Wallace M, Chen R. rTMS for suppressing neuropathic pain: a meta-analysis. J Pain. 2009 Dec;10(12):1205-16. doi: 10.1016/j.jpain.2009.03.010. Epub 2009 May 23. Review. — View Citation

Leung A, Shukla S, Fallah A, Song D, Lin L, Golshan S, Tsai A, Jak A, Polston G, Lee R. Repetitive Transcranial Magnetic Stimulation in Managing Mild Traumatic Brain Injury-Related Headaches. Neuromodulation. 2016 Feb;19(2):133-41. doi: 10.1111/ner.12364. Epub 2015 Nov 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Daily Headache and Pain Log This is a daily self-reporting log that tracks headache, muscle pain, and joint pain levels. The pain levels are scored from 0-10 with 10 being the worst possible pain. 2 months for each subject (11 visits)
Primary Headache Impact Test 6 (HIT-6) This 6-question form assesses the severity of headache pain and is scored with a range of 36-78. The higher score, the higher the impact of headaches on functional ability. 2 months for each subject (11 visits)
Primary 2 months for each subject (11 visits) This assessment has 9 questions about pain level, relief, and interference. Pain level and interference questions range from 0-10, with 10 being the worst. Level of relief has a range of 0-100%, with 100% being complete relief. 2 months for each subject (11 visits)
Primary Opioid Medication Assessment This is a self-reporting log that tracks opioid medication usage. Average daily dosages are converted to equal-potent oral Morphine Sulfate dosage and reported in milligrams. 2 months for each subject (11 visits)
Primary Mechanical-Visual Analogue Scale This scale measures the level of headache, muscle, and joint pain at each visit. This ranges from 0-100, with 100 being the worst possible pain. 2 months for each subject (11 visits)
Secondary Neurobehavioral Symptom Inventory (NSI) This is a 22-question self-report assessment that tracks symptoms over time. Each question ranges from 0-4, with 4 being very severe. The total NSI score ranges from 0-88. 2 months for each subject (11 visits)
Secondary Short-Form McGill Pain Questionnaire (SF-MPQ) This self-reporting survey contains 15 questions that describe the type of pain. Each descriptor is scored between 0-3, with 3 being severe pain. The total score then ranges from 0-45. This questionnaire is filled out one each for joint pain and one for muscle pain. 2 months for each subject (11 visits)
Secondary New Clinical Fibromyalgia Diagnostic Criteria This form contains a checklist of 19 possible areas for muscle pain. The checkmarks are tallied to give the Widespread Pain Index score, which ranges from 0-19. A score of 19 would suggest muscle pain in all 19 possible locations. 2 months for each subject (11 visits)
Secondary Revised Fibromyalgia Impact Questionnaire (FIQR) This 3-part questionnaire measures the level of interference the pain causes, the overall impact of the pain, and intensity of the symptoms. There are a total of 21 questions, each with a range of 0-10, with 10 being either "very difficult" or "always." The FIQR total has a range of 0-210. 2 months for each subject (11 visits)
Secondary Conners Continuous Performance Test 2 (CPT2) This is a 15-minute attention task administered on a laptop. The subject is prompted to press the spacebar as quickly as possible after every letter that appears on the screen except for the letter X. The exam is automatically scored by the program and reports omission rate and response latency. The attentional cognitive function is tracked by their change in these scores over time. 2 months for each subject (11 visits)
Secondary Hopkins Verbal Learning Test (HVLT) This is a memory and recall task that requires the subject to memorize a list of 10 words and recall them. There are 3 trials and they are scored just by the number of words that can be recalled each time, which can be from 0-10 for a total range of 0-30 words. The second part of this test rates their recognition discrimination index by asking if certain words were on the original list. This is scored by taking the number of true positives and subtracting the false positives. The range for this is from 0-12, with 12 indicative of better discrimination within memory. 2 months for each subject (11 visits)
Secondary Trailmaking Test A&B This is a timed test that is administered to assess executive function. Both tests have a series of numbers or numbers and letters that are to be connected in sequential order. The faster the completion time, the better the executive function. 2 months for each subject (11 visits)
Secondary This is a timed test that is administered to assess executive function. Both tests have a series of numbers or numbers and letters that are to be connected in sequential order. The faster the completion time, the better the executive function. This is an administered IQ test that is designed to measure intelligence and cognitive ability in adults and older adolescents. There are several parts to the test, with each response being scored from 0-2 or 0-4 based on the quality of the answer or the completion time. The raw scores are then converted to scaled scores and summed to give the Full Scale score. The higher the Full Scale score, the higher the IQ classification. 2 months for each subject (11 visits)
Secondary Hamilton Rating Scale for Depression This questionnaire rates the severity of depression in 21 questions. Each question either ranges from 0-2 or 0-4. The sum of the scores would give the total score, where a higher score would mean more severe depression. 2 months for each subject (11 visits)
Secondary 36-Item Short Form Survey Instrument (SF-36) This is a 38-question survey that assesses physical function, physical health limitations, emotional problem limitations, fatigue, emotional well-being, social functioning, pain, and general health. The scoring follows the official guidelines by RAND, where certain questions determine each health aspect. The questions are rated from 1-5, and then scored from 0-100. Each health aspect will have a range of 0-100, with 100 suggesting a more favorable health state. 2 months for each subject (11 visits)
Secondary Sleep Quality Assessment (PSQI) This is self-reporting survey has 9 questions and determines the quality and patterns of sleep. Questions are either free-response or have a range from 0-3, with 3 being "more frequent" or "very bad." The responses will be scored based on the guidelines at the bottom of the page. The global PSQI score then has a range of 0-21, with 21 indicative of poor sleep quality. 2 months for each subject (11 visits)
Secondary Insomnia Severity Index This survey has 7 questions that rate the severity of insomnia problems. All questions range from 0-4 and the sum of the answers would give the total score. The total score range from 0-28, with 28 being severe clinical insomnia. 2 months for each subject (11 visits)
Secondary Flinders Fatigue Scale This questionnaire contains 7 questions in order to determine the level of fatigue one is experiencing. The questions range from 1-5, with 5 being "extremely" or "entirely." The higher one scores, the more severe the fatigue. 2 months for each subject (11 visits)
See also
  Status Clinical Trial Phase
Withdrawn NCT03472872 - A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache Phase 4
Withdrawn NCT05410366 - Safe Harbors in Emergency Medicine, Specific Aim 3
Withdrawn NCT02866084 - Neuromodulation Treatment of Vestibular Migraines N/A
Active, not recruiting NCT03537573 - Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care N/A
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Not yet recruiting NCT04352218 - Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache Phase 2
Completed NCT02734992 - Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers N/A
Completed NCT01327118 - Prostaglandin F2alpha in a Human Headache Model N/A
Completed NCT01153789 - Study of Oculomotor Dysfunction Leading to Children Vertigo N/A
Not yet recruiting NCT00969995 - Identification of Inflammatory Markers in Migraine Patients N/A
Not yet recruiting NCT00752921 - Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache Phase 4
Completed NCT00212810 - Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache. Phase 4
Terminated NCT00291395 - PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers Phase 1
Completed NCT00263094 - An End to the Yom Kippur (and Ramadan) Headache N/A
Completed NCT00135122 - Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache Phase 3
Completed NCT02475005 - An Intervention to Improve Adolescent Headache Self-management N/A
Completed NCT03163901 - The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury N/A
Completed NCT01664585 - Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life N/A
Completed NCT04632420 - Evaluation of Headache and Childbirth in a Chronic Pain Population
Recruiting NCT05033613 - Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease